Empowered Patient Podcast

Empowered Patient Podcast

By Karen JagodaScienceMedicineHealth & Fitness
Download on the App Store

Empowered Patient Podcast episodes

  • Advanced Biomaterial Scaffold Provides Alternative for Reconstructive Breast Surgery with Dr. Sanjay Kakkar Tensive TRANSCRIPT

    Dr. Sanjay Kakkar, CEO of Tensive, has developed an innovative bioresorbable polymeric scaffold for breast regeneration following a lumpectomy. The scaffold was designed to address a significant unmet need for breast cancer patients who have limited options for reconstruction. A key feature of this technology is that it facilitates a natural wound-healing response, allowing the body's own vascular, connective, and fat tissues to regrow as the scaffold gradually dissolves.

    Sanjay explains, "What we've been developing at Tensive is at a late clinical stage of these advanced biomaterials, and we've spent the last decade or so pioneering this bioresorbable polymeric scaffold for natural tissue regeneration. So, coming directly to your question, we're on this mission to provide breast cancer survivors with the option of a natural breast reconstruction. What we developed is this resorbable biopolymer that can be implanted at the time of the lumpectomy procedure."

    "But what it does is it replaces volume immediately, and it facilitates new tissue growth without cells or growth factors. This sponge, which is made of a fine scaffold matrix, gradually degrades. So it immediately fills the cavity left by the tumor removal. It facilitates natural tissue regeneration, allowing the body's own cells to grow back into the 97% of empty space, which is formed by this sponge. And that basically means that initially vascular tissue regrows inside the porous architecture, then connective tissue, and then fat comes back."

    #Tensive #BreastCancer #BreastCancerAwareness #ClinicalTrials #ReconstructiveSurgery #REGENERA #BreastHealth #BreastReconstruction #Lumpectomy #Innovation

    tensive.com

    Listen to the podcast here

    0 min
  • Advanced Biomaterial Scaffold Provides Alternative for Reconstructive Breast Surgery with Dr. Sanjay Kakkar Tensive

    Dr. Sanjay Kakkar, CEO of Tensive, has developed an innovative bioresorbable polymeric scaffold for breast regeneration following a lumpectomy. The scaffold was designed to address a significant unmet need for breast cancer patients who have limited options for reconstruction. A key feature of this technology is that it facilitates a natural wound-healing response, allowing the body's own vascular, connective, and fat tissues to regrow as the scaffold gradually dissolves.

    Sanjay explains, "What we've been developing at Tensive is at a late clinical stage of these advanced biomaterials, and we've spent the last decade or so pioneering this bioresorbable polymeric scaffold for natural tissue regeneration. So, coming directly to your question, we're on this mission to provide breast cancer survivors with the option of a natural breast reconstruction. What we developed is this resorbable biopolymer that can be implanted at the time of the lumpectomy procedure."

    "But what it does is it replaces volume immediately, and it facilitates new tissue growth without cells or growth factors. This sponge, which is made of a fine scaffold matrix, gradually degrades. So it immediately fills the cavity left by the tumor removal. It facilitates natural tissue regeneration, allowing the body's own cells to grow back into the 97% of empty space, which is formed by this sponge. And that basically means that initially vascular tissue regrows inside the porous architecture, then connective tissue, and then fat comes back."

    #Tensive #BreastCancer #BreastCancerAwareness #ClinicalTrials #ReconstructiveSurgery #REGENERA #BreastHealth #BreastReconstruction #Lumpectomy #Innovation

    tensive.com

    Download the transcript here

    22 min
  • AI Transforming Medicare Advantage Member Engagement with Dr. Saria Saccocio Essence Healthcare TRANSCRIPT

    Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data.

    Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional benefits that exist and the opportunity to connect with our members is rather unique. In fact, what I'll share with you and the audience is that AI has been a focus for us and a priority as we continue to expand the focus on quality and engagement with our members so that they have their best quality life possible to them. AI is a major piece of this work to make that happen. I can give you a couple of examples. In fact, when it comes to health equity, CMS has recently required Medicare plans to ensure that we are analyzing our data through a health equity lens. This year, in fact, we're focused on authorizations, authorizations of care. We want to make sure that it is critical to our members and AI. I see an opportunity to recognize any blind spots or implicit bias."

    "I think that every human being has a capability for technology. And what's critical is that we meet them where they are, that we understand what they want, what they need out of technology. I think that works as well as providers. As you see all of these AI developers starting up companies and solving problems, the conversation that we're having every day at Lumeris and at Essence Healthcare is what does the patient want? What does that member need for quality of care? And then engage and include the providers in that conversation. What makes their job easier? Because one of the challenges with new technology is that we can also reach a point of technology exhaustion. So I'll give an example of our relationship with Oura ring, the wearable device that tracks for sleep, for health, for heart rate, and a number of different measures."

    #EssenceHealthcare #MedicareAdvantage #HealthAI #OuraRing #DigitalHealth

    essencehealthcare.com

    Listen to the podcast here

    0 min
  • AI Transforming Medicare Advantage Member Engagement with Dr. Saria Saccocio Essence Healthcare

    Dr. Saria Saccocio, Chief Medical Officer at Essence Healthcare, is using AI to enhance care and services for patients who are enrolled in Medicare Advantage programs. One application is to analyze data related to health equity, care authorization, and to address biases. Their AI agent is being used to interact with patients, offering them the option to access a human. Integration with wearables, such as the Oura Ring, focuses on identifying clinically useful information to prevent physicians from being overwhelmed by data.

    Saria explains, "Medicare Advantage plans are absolutely that. It's an advantage because of the additional benefits that exist and the opportunity to connect with our members is rather unique. In fact, what I'll share with you and the audience is that AI has been a focus for us and a priority as we continue to expand the focus on quality and engagement with our members so that they have their best quality life possible to them. AI is a major piece of this work to make that happen. I can give you a couple of examples. In fact, when it comes to health equity, CMS has recently required Medicare plans to ensure that we are analyzing our data through a health equity lens. This year, in fact, we're focused on authorizations, authorizations of care. We want to make sure that it is critical to our members and AI. I see an opportunity to recognize any blind spots or implicit bias."

    "I think that every human being has a capability for technology. And what's critical is that we meet them where they are, that we understand what they want, what they need out of technology. I think that works as well as providers. As you see all of these AI developers starting up companies and solving problems, the conversation that we're having every day at Lumeris and at Essence Healthcare is what does the patient want? What does that member need for quality of care? And then engage and include the providers in that conversation. What makes their job easier? Because one of the challenges with new technology is that we can also reach a point of technology exhaustion. So I'll give an example of our relationship with Oura ring, the wearable device that tracks for sleep, for health, for heart rate, and a number of different measures."

    #EssenceHealthcare #MedicareAdvantage #HealthAI #OuraRing #DigitalHealth

    essencehealthcare.com

    Download the transcript here

    20 min
  • Specialty Pharmacies Altering Rare Disease Care with Kerry Mello-Parker Shields Health TRANSCRIPT

    Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing.

    Kerry explains, "Shields Health Solutions is a specialty pharmacy accelerator. We partner with over 80 health systems across the United States. We support them in establishing and growing a specialty pharmacy. We help them to access critical medications. Some of them are not available at traditional pharmacies, and we support them in managing clinical quality care programs for their patients."

    "I'd like to step back a little and talk about what a rare disease is and how we define it. Currently, it is defined as a condition that affects fewer than 200,000 people. However, over 7,000 rare diseases exist. So when we do the math, we come to see that they are not so rare. And some estimates show that up to 10% of the US population may actually have a rare disease. And what I've seen is that there are really three main complexities of treating rare diseases and challenges that patients may face. One of them is that there is a lack of available treatment options when compared with more common diseases. So, for example, only about 10% of rare diseases have an FDA-approved treatment option, but that is changing. We have the Orphan Drug Act, which has actually changed the landscape. It has incentivized and facilitated the development of medications to treat rare diseases."

    #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #RareDiseases #MedicationAdherence

    shieldshealthsolutions.com

    Listen to the podcast here

    0 min
  • Specialty Pharmacies Altering Rare Disease Care with Kerry Mello-Parker Shields Health

    Kerry Mello-Parker, Director of Rare Diseases and REMS programs at Shields Health Solutions, addresses the complexities and challenges faced by patients with rare diseases including diagnostic delays and limited access to medication. Using an integrated specialty pharmacy model, Shields works with pharmacists to have direct access to the EHR, enabling better patient monitoring, shorter time to initiate medication, tracking outcomes, and providing patients with a direct line of communication to their care team. Pharmacists treating rare diseases are also supported with specialized information on medication administration, side effects and complex billing.

    Kerry explains, "Shields Health Solutions is a specialty pharmacy accelerator. We partner with over 80 health systems across the United States. We support them in establishing and growing a specialty pharmacy. We help them to access critical medications. Some of them are not available at traditional pharmacies, and we support them in managing clinical quality care programs for their patients."

    "I'd like to step back a little and talk about what a rare disease is and how we define it. Currently, it is defined as a condition that affects fewer than 200,000 people. However, over 7,000 rare diseases exist. So when we do the math, we come to see that they are not so rare. And some estimates show that up to 10% of the US population may actually have a rare disease. And what I've seen is that there are really three main complexities of treating rare diseases and challenges that patients may face. One of them is that there is a lack of available treatment options when compared with more common diseases. So, for example, only about 10% of rare diseases have an FDA-approved treatment option, but that is changing. We have the Orphan Drug Act, which has actually changed the landscape. It has incentivized and facilitated the development of medications to treat rare diseases."

    #ShieldsHealthSolutions #IntegratedCareModel #SpecialtyPharmacy #RareDiseases #MedicationAdherence

    shieldshealthsolutions.com

    Download the transcript here

    20 min
  • AI-Driven Platforms Breaking Down Healthcare Data Silos with Ram Sahasranam Fold Health TRANSCRIPT

    Ram Sahasranam, President and Co-Founder of Fold Health, has created a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders.

    Ram explains, "The way to look at it is that empowering providers and patients need to go hand in hand. That is the fundamental reason why we called ourselves Fold Health, which is that healthcare needs to fold around the providers and the team supporting the providers and the patients and the families of the patients who are involved in the care. We have seen healthcare go from $1.6 trillion in spending to $5.3 trillion in spending this year. But in those 15 years, we haven't yet seen it fold around the two most important people, the provider or the patient, in terms of better outcomes or improving the burnout rates that clinicians and their teams face today."

    "So the fundamental challenge that we noticed was that multiple people were living in different systems and hence different silos from a data standpoint. So the clinician did not know what was happening with their care teams. The patient was living in a different system. If the patient goes to a specialist, the data comes in a compressed format to the physician in an easily digestible manner, which was a challenge. So what Fold does as a result of getting control of all these different nodes is that data can be used to summarize and provide things for the different teams in a quick, easily digestible manner."

    #Foldhealth #CareCoordination #CareDelivery #ConnectedCare #HealthTech #AI #HealthAI

    Fold.Health

    Listen to the podcast here

    0 min
  • AI-Driven Platforms Breaking Down Healthcare Data Silos with Ram Sahasranam Fold Health

    Ram Sahasranam, President and Co-Founder of Fold Health, has created a platform that integrates with the EHR to create an AI-driven interface that streamlines workflows, improves communication across the care team, and helps better manage patient care. Traditional EHR systems, while effective for documentation, were not built for proactive care and data sharing. With a focus on the patient and providers, Fold Health is integrating data sources and automating redundant administrative tasks helping to reduce clinician burnout and improve patient communication for scheduling and reminders.

    Ram explains, "The way to look at it is that empowering providers and patients need to go hand in hand. That is the fundamental reason why we called ourselves Fold Health, which is that healthcare needs to fold around the providers and the team supporting the providers and the patients and the families of the patients who are involved in the care. We have seen healthcare go from $1.6 trillion in spending to $5.3 trillion in spending this year. But in those 15 years, we haven't yet seen it fold around the two most important people, the provider or the patient, in terms of better outcomes or improving the burnout rates that clinicians and their teams face today."

    "So the fundamental challenge that we noticed was that multiple people were living in different systems and hence different silos from a data standpoint. So the clinician did not know what was happening with their care teams. The patient was living in a different system. If the patient goes to a specialist, the data comes in a compressed format to the physician in an easily digestible manner, which was a challenge. So what Fold does as a result of getting control of all these different nodes is that data can be used to summarize and provide things for the different teams in a quick, easily digestible manner."

    #Foldhealth #CareCoordination #CareDelivery #ConnectedCare #HealthTech #AI #HealthAI

    Fold.Health

    Download the transcript here

    18 min
  • Operational Efficiency Needed to Overcome Impact of Tariffs and Reimbursement Cuts on Struggling Hospitals with Ralph Keiser ArcheHealth TRANSCRIPT

    Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs. ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care.

    Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line."

    "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer."

    #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations

    archehealth.ai

    Listen to the podcast here

    0 min
  • Operational Efficiency Needed to Overcome Impact of Tariffs and Reimbursement Cuts on Struggling Hospitals with Ralph Keiser ArcheHealth

    Ralph Keiser, CEO of ArcheHealth, highlights the severe financial pressures that hospitals are confronting as a result of rising costs and declining reimbursements. Reductions in reimbursements are threatening hospitals that serve underinsured populations. Costs are increasing due to tariffs on medical device components and the general price inflation on medical supplies and drugs. ArcheHealth is focused on helping hospitals improve operational efficiency to lower the expense of delivering care.

    Ralph explains, "The tariff index is going to come mostly around medical devices and device components. So plastics, metals, packaging, things that the device manufacturers use to deliver their products to hospitals and health systems, those will likely get passed through. It won't be huge incremental costs, so there will be additional costs due to tariffs. It depends on a couple of things. Do you have a strong contract that sort of embargoes your current price? Then maybe in the next contract term you'll see that pass through or the contract so the supplier to pass through, you'll see them. We're monitoring month by month the current or last month's spend was on these items, and do we see a chart impact by manufacturer by line."

    "One thing that I want to make sure we talk about, too, isn't just shared impact. So the cost to a hospital for devices and drugs averaged 8.9% more in 2024. So just by nature of the market raising its prices for goods that hospitals use to cover patient care, those moved up without tariffs 8.9% last year. We think we're tracking increases that are happening despite the tariff overlay or on top of the tariffs. We still think that the pressure on hospitals is due to the price of therapeutics, and is going to continue to go up, tariff or not. And so I want to mention that because this is the ongoing impact of the cost of MedTech and drugs that gets passed through to the consumer."

    #ArcheHealth #AIinHealthcare #HealthTech #HealthcareOperations

    archehealth.ai

    Download the transcript here

    18 min

About Empowered Patient Podcast

From the publisher's feed

Empowered Patient Podcast with Karen Jagoda is a window into the latest innovations in digital health, the changing dynamic between doctors and patients, and the emergence of precision medicine. Theโ€ฆ

More shows like Empowered Patient Podcast

Rheumatology For The Royal College by Dr. Karim Ladak

Rheumatology For The Royal College

182 Listeners